Allogene Therapeutics
Maurice Cheung is a quality control specialist at Allogene Therapeutics, with extensive experience in the biotechnology sector, including roles at IGM Biosciences, Audentes Therapeutics, and Genentech, where responsibilities included maintaining GMP compliance, ensuring audit readiness, and utilizing various laboratory management systems. Maurice has demonstrated expertise in quality control processes, ergonomic practices, and laboratory safety as a Lab Safety Ergo Advocate. Additionally, experience as a bilingual education specialist at the California Academy of Sciences involved developing and delivering science programs in Chinese for elementary students. Maurice holds a Bachelor of Arts in Molecular and Cell Biology from the University of California, Berkeley.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.